JPWO2025211357A5 - - Google Patents

Info

Publication number
JPWO2025211357A5
JPWO2025211357A5 JP2025558591A JP2025558591A JPWO2025211357A5 JP WO2025211357 A5 JPWO2025211357 A5 JP WO2025211357A5 JP 2025558591 A JP2025558591 A JP 2025558591A JP 2025558591 A JP2025558591 A JP 2025558591A JP WO2025211357 A5 JPWO2025211357 A5 JP WO2025211357A5
Authority
JP
Japan
Prior art keywords
agent according
nucleic acid
acid encoding
fragment
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025558591A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025211357A1 (cg-RX-API-DMAC7.html
JP7868817B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2025/013342 external-priority patent/WO2025211357A1/ja
Publication of JPWO2025211357A1 publication Critical patent/JPWO2025211357A1/ja
Publication of JPWO2025211357A5 publication Critical patent/JPWO2025211357A5/ja
Application granted granted Critical
Publication of JP7868817B2 publication Critical patent/JP7868817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025558591A 2024-04-02 2025-04-01 糖尿病に対するsHB-EGF強化治療 Active JP7868817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2024059835 2024-04-02
JP2024059835 2024-04-02
PCT/JP2025/013342 WO2025211357A1 (ja) 2024-04-02 2025-04-01 糖尿病に対するsHB-EGF強化治療

Publications (3)

Publication Number Publication Date
JPWO2025211357A1 JPWO2025211357A1 (cg-RX-API-DMAC7.html) 2025-10-09
JPWO2025211357A5 true JPWO2025211357A5 (cg-RX-API-DMAC7.html) 2026-03-11
JP7868817B2 JP7868817B2 (ja) 2026-06-02

Family

ID=97267051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025558591A Active JP7868817B2 (ja) 2024-04-02 2025-04-01 糖尿病に対するsHB-EGF強化治療

Country Status (3)

Country Link
JP (1) JP7868817B2 (cg-RX-API-DMAC7.html)
TW (1) TW202602484A (cg-RX-API-DMAC7.html)
WO (1) WO2025211357A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839476B2 (ja) * 2005-09-28 2011-12-21 国立大学法人 鹿児島大学 ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
JP2007223939A (ja) * 2006-02-22 2007-09-06 Kobe Univ エネルギー代謝促進因子としてのhb−egfの使用
CN113382775A (zh) * 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
US20240173381A1 (en) * 2021-03-03 2024-05-30 Kagoshima University Hb-egf gene therapy for diabetes

Similar Documents

Publication Publication Date Title
Van Adel et al. Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time
Kupatt et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion: role of vessel maturation
Schwiebert et al. Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression
US20080254109A1 (en) Localized myocardial injection method for treating ischemic myocardium
Korecka et al. Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson's disease
Liu et al. Application of recombinant adenovirus for in vivo gene delivery to spinal cord
JP2023517934A5 (cg-RX-API-DMAC7.html)
Finiels et al. Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases
AU2012333408B2 (en) Gene therapy for diabetic neuropathy using an HGF isoform
JP2018527941A5 (cg-RX-API-DMAC7.html)
WO1999006562A1 (en) Method enabling readministration of aav vector via immunosuppression of host
US20030100889A1 (en) Method of administration of a gene of interest to a vascular tissue
JP2024546641A5 (cg-RX-API-DMAC7.html)
JP2021533801A5 (cg-RX-API-DMAC7.html)
EP1132098B1 (en) Gene therapy for cerebrovascular disorders
JP2023545731A5 (cg-RX-API-DMAC7.html)
JPWO2022186282A5 (cg-RX-API-DMAC7.html)
JP2022060514A (ja) ガバペンチノイドからの干渉が減少し、hgf異型体を発現するdnaコンストラクトを用いる神経病症の治療
Sakuraba et al. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis
US6641807B1 (en) Adenoviral vectors encoding erythropoietin and their use in gene therapy
Hayashi et al. Adenoviral gene transfer of hepatocyte growth factor prevents death of injured adult motoneurons after peripheral nerve avulsion
Kawakami et al. Expression of hepatocyte growth factor in normal and carbon tetrachloride–treated monkeys
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
Acsadi et al. Interferons impair early transgene expression by adenovirus-mediated gene transfer in muscle cells
CN102741277A (zh) 在治疗运动神经元疾病中的IFNγ抑制剂